Form 4: C4 Therapeutics Director Ronald Cooper Granted 35,500 Stock Options

C4 Therapeutics, Inc. Director Ronald Harold Wilfred Cooper was granted 35,500 stock options with an exercise price of $1.44 per share, vesting over approximately one year.

Summary

• Ronald Harold Wilfred Cooper, a Director of C4 Therapeutics, Inc. (CCCC), was granted 35,500 stock options.
• The options have an exercise price of $1.44 per share.
• The transaction date for this grant was June 18, 2025.
• The options will vest in full upon the earlier of June 18, 2026, or the date of the next annual meeting of the Issuer's stockholders.
• Vesting is contingent upon Mr. Cooper's continued service as a member of the Board on the vesting date.
• The expiration date for these stock options is June 17, 2035.
• Following this transaction, Mr. Cooper beneficially owns 35,500 direct stock options.

Sentiment

Score: 6

Explanation: The document reports a routine compensation event (stock option grant) to a director, which is generally viewed as a neutral to slightly positive event as it aligns insider interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operational status.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.

Future Outlook

The stock options are set to vest in full upon the earlier of June 18, 2026, or the next annual meeting of the Issuer's stockholders, subject to the director's continued service.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of equity compensation to attract and retain talent and align leadership interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, tied to continued service and a specific future date or corporate event (annual meeting), is typical for such grants, aiming to retain key personnel.

Corporate Governance

Related Party Transactions

• The grant of 35,500 stock options to Ronald Harold Wilfred Cooper, a Director of C4 Therapeutics, Inc., constitutes a transaction with a related party (an insider) as part of his compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by tying a portion of his compensation to the company's stock performance.
• Employees: While not directly impacting employees, such grants are part of a broader compensation philosophy that can influence overall company culture and talent retention strategies.

Next Steps

• The stock options will vest upon the earlier of June 18, 2026, or the next annual meeting of C4 Therapeutics, Inc. stockholders, provided Ronald Harold Wilfred Cooper continues his service on the Board.

Key Dates

Keywords

C4 Therapeutics, CCCC, Stock Option Grant, Director Compensation, Insider Transaction, Form 4, Beneficial Ownership